Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27223443 | 0.98 | KMT2A (0.55) | KMT2AALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL2579474 | 0.83 | KMT2A (0.43) | KMT2AALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL1156163 | 0.83 | KMT2A (0.58) | KMT2AALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL2069470 | 0.81 | KMT2A (0.56) | KMT2AALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL163150 | 0.81 | KMT2A (0.56) | KMT2AALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL8268881 | 0.80 | KMT2A (0.68) | KMT2AALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL30717961 | 0.80 | KMT2A (0.55) | KMT2AALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL13272035 | 0.80 | KMT2A (0.55) | KMT2AALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL9918655 | 0.80 | KMT2A (0.55) | KMT2AALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL6219929 | 0.79 | ALDH1A1 (0.56) | KMT2AALDH1A1HSD17B10MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021103257-A1 | CONTINUOUS PREPARATION METHOD FOR 2-AMINO-PYRROLE-3-CARBOXYLATE | 凯莱英生命科学技术(天津)有限公司 | 2021-06-03 | — | — | WO | claimed |
| CN-110627701-B | Continuous preparation method of 2-aminopyrrole-3-carboxylic acid ethyl ester | 凯莱英生命科学技术(天津)有限公司 | 2020-03-31 | — | — | CN | claimed |
| CN-110627701-A | Continuous preparation method of 2-aminopyrrole-3-carboxylic acid ethyl ester | 凯莱英生命科学技术(天津)有限公司 | 2019-12-31 | — | — | CN | claimed |
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4472967-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118973581-A | IRAK degradation agent and application thereof | 凯麦拉医疗公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-118754861-A | Substituted alkynylene compounds as anticancer agents | 奥里吉恩肿瘤学有限公司 | 2024-10-11 | — | — | CN | disclosed |
| US-12091411-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240262831-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-08-08 | — | — | US | disclosed |
| CN-118401507-A | Inhibitors targeting ubiquitin-specific protease 7 (USP 7) | 丹娜法伯癌症研究院 | 2024-07-26 | — | — | CN | disclosed |
| EP-1572113-A4 | CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-11-22 | — | — | EP | disclosed |
| CN-1771231-A | Calcium receptor modulating compounds and uses thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-05-10 | — | — | CN | disclosed |
| US-20060079536-A1 | Calcium receptor modulating compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-13 | — | — | US | disclosed |
| EP-1572113-A2 | CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004017908-A2 | CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-04 | — | — | WO | disclosed |
| EP-0836605-B1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | disclosed |
| US-6140332-A | Pyrrolopyrimidines and processes for the preparation thereof | NOVARTIS AG (CH) | 2000-10-31 | — | — | US | disclosed |
| EP-0836605-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002266-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885ALDH1A1 2776/4885HSD17B10 2107/4885 |
| US-20060079536-A1 | Calcium receptor modulating compound and use thereof | CASR, NR2C2, CALCR | KMT2A 2825/4885ALDH1A1 4167/4885HSD17B10 1563/4885 |
| US-12091411-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885ALDH1A1 2776/4885HSD17B10 2107/4885 |
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | USP7, USP47, USP2 | KMT2A 1939/4885ALDH1A1 2692/4885HSD17B10 2030/4885 |
| US-20240262831-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | NLN, OAT, PC | KMT2A 2565/4885ALDH1A1 460/4885HSD17B10 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.